Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure

European Journal of Heart Failure

Volumn 16, Issue 10, 2014, Pages 1056-1065

  Li, Meihua ^a   Zheng, Can ^a   Kawada, Toru ^a   Inagaki, Masashi ^a   Uemura, Kazunori ^a   Sugimachi, Masaru ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Donepezil; Heart failure; Losartan; Myocardial infarction; Survival

Indexed keywords

ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; DONEPEZIL; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CAPILLARY DENSITY; CONTROLLED STUDY; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HYPOTENSION; LONG TERM SURVIVAL; MALE; NONHUMAN; OVERALL SURVIVAL; RAT; TREATMENT OUTCOME; ANIMAL; CHRONIC DISEASE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VAGUS NERVE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CHOLINESTERASE INHIBITORS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEART FAILURE; INDANS; LOSARTAN; MYOCARDIAL INFARCTION; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VAGUS NERVE;

EID: 84907977245     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.164     Document Type: Article

References (48)

1. Packer M,. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
2. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ,. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991; 18: 464-472.
3. Mann DL,. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100: 999-1008.
4. Braunwald E, Bristow MR,. Congestive heart failure: fifty years of progress. Circulation 2000; 102: IV14-IV23.
5. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43: 1534-1541.
6. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW,. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794.
7. Pepper GS, Lee RW,. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med 1999; 159: 225-234.
8. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydon L, Thygesen K, Uretsky BF,. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
9. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pendersen C, Ball S, Pogue J, Moye L, Braunwald E,. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.
10. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA,. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-1848.
11. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW, Goff DC, Grover FL, Malenka DJ, Peterson ED, Redberg RF,. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 2005; 112: 1888-1916.
12. Hall MJ, Levant S, DeFrances CJ,. Hospitalization for congestive heart failure: United States. NCHS Data Brief 2000-2010; 2012: 1-8.
13. Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, Pozzoli M, Opasich C, Tavazzi L,. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997; 96: 3450-3458.
14. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ,. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.
15. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K,. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004; 109: 120-124.
16. Li M, Zheng C, Inagaki M, Kawada T, Sunagawa K, Sugimachi M,. Chronic vagal stimulation decreased vasopressin secretion and sodium ingestion in heart failure rats after myocardial infarction. Conf Proc IEEE Eng Med Biol Soc 2005; 4: 3962-3965.
17. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ,. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011; 32: 847-855.
18. Schwartz PJ,. Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Neth Heart J 2013; 21: 82-84.
19. Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, Montastruc JL, Rascol O,. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol 1998; 361: 61-71.
20. Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD,. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart 2003; 89: 854-858.
21. Okazaki Y, Zheng C, Li M, Sugimachi M,. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 2010; 60: 67-74.
22. Li M, Zheng C, Kawada T, Inagaki M, Uemura K, Shishido T, Sugimachi M,. Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction. Circ J 2013; 77: 2519-2525.
23. Lefebvre F, Préfontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J,. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond) 2006; 111: 217-224.
24. Kawada T, Li M, Kamiya A, Shimizu S, Uemura K, Yamamoto H, Sugimachi M,. Open-loop dynamic and static characteristics of the carotid sinus baroreflex in rats with chronic heart failure after myocardial infarction. J Physiol Sci 2010; 60: 283-298.
25. Suga H,. Ventricular energetics. Physiol Rev 1990; 70: 247-277.
26. Bristow MR,. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011; 109: 1176-1194.
27. Swedberg K1, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
28. Matsuura W, Sugimachi M, Kawada T, Sato T, Shishido T, Miyano H, Nakahara T, Ikeda Y, Alexander J Jr, Snagawa K,. Vagal stimulation decreases left ventricular contractility mainly through negative chronotropic effect. Am J Physiol 1997; 273: H534-H539.
29. Nakayama Y, Miyano H, Shishido T, Inagaki M, Kawada T, Sugimachi M, Sunagawa K,. Heart rate-independent vagal effect on end-systolic elastance of the canine left ventricle under various levels of sympathetic tone. Circulation 2001; 104: 2277-2279.
30. Joaquim LF, Farah VM, Bernatova I, Fazan R Jr, Grubbs R, Morris M,. Enhanced heart rate variability and baroreflex index after stress and cholinesterase inhibition in mice. Am J Physiol Heart Circ Physiol 2004; 287: H251-H257.
31. Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA,. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol 2006; 23: 476-481.
32. Rosas-Ballina M, Tracey KJ,. Cholinergic control of inflammation. J Intern Med 2009; 265: 663-679.
33. Mann DL,. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
34. Springer J, Okonko DO, Anker SD,. Vagal nerve stimulation in chronic heart failure: an antiinflammatory intervention? Circulation 2004; 110:e34; author reply e34.
35. Schellings MW, Pinto YM, Heymans S,. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31.
36. Ertl G, Frantz S,. Healing after myocardial infarction. Cardiovasc Res 2005; 66: 22-32.
37. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP,. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110: 527-536.
38. Zheng W, Brown MD, Brock TA, Bjercke RJ, Tomanek RJ,. Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. Circ Res 1999; 85: 192-198.
39. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S,. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996; 27: 714-719.
40. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
41. Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF,. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 1999; 41: 100-108.
42. Takahashi M, Tanonaka K, Yoshida H, Oikawa R, Koshimizu M, Daicho T, Toyo-Oka T, Takeo S,. Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. Cardiovasc Res 2005; 65: 356-365.
43. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A,. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
44. Lanctôt PM, Leclerc PC, Escher E, Leduc R, Guillemette G,. Role of N-glycosylation in the expression and functional properties of human AT1 receptor. Biochemistry 1999; 38: 8621-8627.
45. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P,. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412.
46. Ahmet I, Morrell C, Lakatta EG, Talan MI,. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 2009; 331: 178-185.
47. White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA,. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005; 112: 3391-3399.
48. Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M,. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013; 34: 2585-2591.